FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Fresenius Kabi Recalls Ivenix Infusion Software

[ Price : $8.95]

Fresenius Kabi recalls its Ivenix LVP software that is embedded in its Ivenix Infusion System due to reports about certain anomali...

Plus Therapeutics Gets Orphan Statis for Radiotherapy

[ Price : $8.95]

FDA grants Plus Therapeutics an orphan drug designation for Rhenium (186Re) Obisbemeda, a radiotherapy for treating leptomeningeal...

FDA Clears Zimmer Persona Knee Implant

[ Price : $8.95]

FDA clears a Zimmer Biomet 510(k) for its Persona Revision SoluTion Femur, a revision knee implant for patients who have sensitivi...

FDA Denys Hearing on Vanda Hetlioz Rejection

[ Price : $8.95]

Federal Register notice: FDA makes available its decision to deny a request for a hearing on a CDER recent refusal to approve a Va...

J&J Stops Phase 3 Depression Drug Program

[ Price : $8.95]

Johnson & Johnson stops its Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depress...

FDA Domestic Inspections Fall, Foreign Rise: Study

[ Price : $8.95]

Consultants from Eliquent Life Sciences say most of FDAs drug inspection-based Warning Letters issued in fiscal year 2024 went to ...

Celltrion BLA for Interchangeable Xolair Biosimilar

[ Price : $8.95]

FDA approves a Celltrion BLA for Omlyclo, the first interchangeable biosimilar to Genentechs Xolair (omalizumab).

FDA Nixes Vanda Hetlioz Hearing

[ Price : $8.95]

FDA denies a hearing on Vandas Hetlioz sNDA and proceeds with its rejection of the filing.

Nuwellis AquaFlexFlow Recall is Class 1

[ Price : $8.95]

FDA says a Nuwellis 12/2024 recall of certain lots of its extracorporeal blood circuits is Class 1.

FDA OKs Gene Therapy for Retinal Disease

[ Price : $8.95]

FDA approves a Neurotech Pharmaceuticals BLA for Encelto (revakinagene taroretcel-lwey) for treating macular telangiectasia Type 2...